Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
5.33 USD | -2.20% | -8.89% | -5.66% |
Mar. 14 | Monte Rosa Therapeutics Q4 Net Loss Narrows; Shares Decline | MT |
Mar. 14 | Monte Rosa Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023 | CI |
Evolution of the average Target Price on Monte Rosa Therapeutics, Inc.
Price target over the last 5 years
History of analyst recommendation changes
Analysts' Consensus
Consensus detail
Consensus revision (last 18 months)
Analysts covering Monte Rosa Therapeutics, Inc.
Wedbush | |
Credit Suisse | |
Wells Fargo Securities | |
UBS | |
Jefferies & Co. | |
Piper Sandler | |
Berenberg Bank | |
Guggenheim | |
SVB Leerink | |
Cowen | |
JPMorgan Chase |
EPS Revisions
- Stock Market
- Equities
- GLUE Stock
- Consensus Monte Rosa Therapeutics, Inc.